Free Trial
NASDAQ:INZY

Inozyme Pharma Q1 2024 Earnings Report

Inozyme Pharma EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.35
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Inozyme Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Inozyme Pharma Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 7, 2024
Conference Call Time
7:00AM ET

Inozyme Pharma Earnings Headlines

Inozyme Pharma Inc News (INZY) - Investing.com
HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
Inozyme Pharma Inc Ordinary Shares
See More Inozyme Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inozyme Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inozyme Pharma and other key companies, straight to your email.

About Inozyme Pharma

Inozyme Pharma (NASDAQ:INZY), a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

View Inozyme Pharma Profile

More Earnings Resources from MarketBeat